Biotech Values

[DewDiligence]

TDLP’s trial failed—from today’s PR:

Analysis of the Intent-to-Treat (ITT) population of the primary efficacy endpoint…favored Ketotransdel® compared to placebo but not to a degree that reached statistical significance. We believe that this finding was not due to a lack of effect of Ketotransdel®, but rather due to patient compliance issues, non-adherence to protocol procedures and other potentially confounding factors… [blah, blah, blah]

Probably a good time to stop your pumping and begin dumping.